School of Pharmacy : Shekh-Ahmad Tawfeeq

(1) Sandouka S, Saadi A, Singh PK, Olowe R, Shekh-Ahmad T. Nrf2 is predominantly expressed in hippocampal neurons in a rat model of temporal lobe epilepsy. Cell Biosci 2023;13(1).

(2) Singh PK, Saadi A, Sheeni Y, Shekh-Ahmad T. Specific inhibition of NADPH oxidase 2 modifies chronic epilepsy. Redox Biol 2022;58.

(3) Qiu Y, O’Neill N, Maffei B, Zourray C, Almacellas-Barbanoj A, Carpenter JC, et al. On-demand cell-autonomous gene therapy for brain circuit disorders. Sci 2022;378(6619):523-532.

(4) Saadi A, Sandouka S, Grad E, Singh PK, Shekh-Ahmad T. Spatial, temporal, and cell-type-specific expression of NADPH Oxidase isoforms following seizure models in rats. Free Radic Biol Med 2022;190:158-168.

(5) Sandouka S, Shekh-Ahmad T. Induction of the nrf2 pathway by sulforaphane is neuroprotective in a rat temporal lobe epilepsy model. Antioxidants 2021;10(11).

(6) Olowe R, Sandouka S, Saadi A, Shekh‐ahmad T. Approaches for reactive oxygen species and oxidative stress quantification in epilepsy. Antioxidants 2020;9(10):1-26.

(7) Shekh-Ahmad T, Kovac S, Abramov AY, Walker MC. Reactive oxygen species in status epilepticus. Epilepsy Behav 2019;101.

(8) Shekh-Ahmad T, Lieb A, Kovac S, Gola L, Wigley WC, Abramov AY, et al. Combination antioxidant therapy prevents epileptogenesis and modifies chronic epilepsy. Redox Biol 2019;26.

(9) Pauletti A, Terrone G, Shekh-Ahmad T, Salamone A, Ravizza T, Rizzi M, et al. Notice of retraction: Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy (Brain (2017) 140, (1885–1899) DOI:10.1093/Brain/awx117). Brain 2019;142(7).

(10) Pauletti A, Terrone G, Shekh-Ahmad T, Salamone A, Ravizza T, Rizzi M, et al. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain 2019;142(7).

(11) Snowball A, Chabrol E, Wykes RC, Shekh-Ahmad T, Cornford JH, Lieb A, et al. Epilepsy gene therapy using an engineered potassium channel. J Neurosci 2019;39(16):3159-3169.

(12) Khan AA, Shekh-Ahmad T, Khalil A, Walker MC, Ali AB. Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model. Br J Pharmacol 2018;175(11):2097-2115.

(13) Shekh-Ahmad T, Eckel R, Dayalan Naidu S, Higgins M, Yamamoto M, DInkova-Kostova AT, et al. KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy. Brain 2018;141(5):1390-1403.

(14) Pauletti A, Terrone G, Shekh-Ahmad T, Salamone A, Ravizza T, Rizzi M, et al. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain 2017;140(7):1885-1899.

(15) Weiser M, Levi L, Levine SZ, Bialer M, Shekh-Ahmad T, Matei V, et al. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disord 2017;19(4):285-294.

(16) Mawasi H, Bibi D, Shekh-Ahmad T, Shaul C, Blotnik S, Bialer M. Pharmacokinetic-pharmacodynamic correlation and brain penetration of sec-butylpropylacetamide, a new CNS drug possessing unique activity against status epilepticus. Mol Pharm 2016;13(7):2492-2496.

(17) Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav 2015;49:298-302.

(18) Mawasi H, Shekh-Ahmad T, Finnell RH, Wlodarczyk BJ, Bialer M. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide - Amide derivatives of valproic acid. Epilepsy Behav 2015;46:72-78.

(19) Shekh-Ahmad T, Mawasi H, McDonough JH, Finnell RH, Wlodarczyk BJ, Yavin E, et al. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia 2014;55(12):1944-1952.

(20) Bar-Klein G, Swissa E, Kamintsky L, Shekh-Ahmad T, Saar-Ashkenazy R, Hubary Y, et al. Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia 2014;55(12):1953-1958.

(21) Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014;55(2):353-361.

(22) Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia 2013;54(SUPPL. 6):99-102.

(23) Neuman MG, Nanau RM, Shekh-Ahmad T, Yagen B, Bialer M. Valproic acid derivatives signal for apoptosis and repair in vitro. Clin Biochem 2013;46(15):1532-1537.

(24) Hen N, Shekh-Ahmad T, Yagen B, McDonough JH, Finnell RH, Wlodarczyk B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec -butylpropylacetamide (SPD), a new CNS-Active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013;56(16):6467-6477.

(25) Bialer M, Shekh-Ahmad T, Braun TL, Halvorsen MB. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013;54(8):1444-1452.

(26) Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013;231:145-156.

(27) Shekh-Ahmad T, Bialer M, Yavin E. Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. Epilepsy Res 2012;98(2-3):238-246.

(28) White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012;53(1):134-146.

(29) Lambrecht LJ, Shekh-Ahmad T, Todd WM, Halvorsen MB, Bialer M. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 2011;52(10):1877-1883.